logo
This Is the Type of Fat You *Want* To Have To Stay Healthy as You Age

This Is the Type of Fat You *Want* To Have To Stay Healthy as You Age

Yahoo2 days ago
This Is the Type of Fat You *Want* To Have To Stay Healthy as You Age originally appeared on Parade.
Body fat gets a bad rap when it comes to health—we're all always on a mission to get rid of belly fat! But it turns out that not all forms of fat are bad for healthy aging. As you've likely heard from your doctor or other health pros, maintaining healthy body fat levels, and potentially even more importantly, having (and maintaining) healthy muscle mass levels via strength training as you age can help reduce your risk of premature death by up to 17 percent. And while muscle mass is a key indicator of healthy longevity, new research from Rutgers University shows that a certain type of fat could be a game changer in how active you remain as you age and help promote longevity. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊
A recent study published in Aging Cell found that mice that had a specific form of brown fat tissue (which they had due to a missing gene) had better exercise capacity as they aged and increased longevity and lifespan by about 30 percent. The scientists working on the study transplanted some of the special brown fat to other mice that were not genetically modified and found that the normal mice responded within days, showing similar benefits.
Related:
The special type of fat researchers found had a positive health effect is brown fat, which is not a new discovery (although the fat they studied was a more potent type of it). The body has two main types of fat, FYI: white fat (AKA the "bad" kind known to contribute to health issues) and brown fat, or brown adipose tissue (BAT). "Unlike white adipose tissue, which stores energy, BAT burns calories to generate heat—a process driven by its rich mitochondrial content and the presence of uncoupling protein 1 (UCP1)," says Ingrid Yang, MD, a board-certified internal medicine physician and longevity science expert. "This thermogenic capability not only helps in temperature regulation but has also been linked to improved metabolic outcomes. Recent research has shown that BAT activation may enhance insulin sensitivity and protect against metabolic diseases, such as obesity and diabetes, which are key factors in age-related health decline," she says.
While brown fat is not a new discovery, the study brings a new understanding of how brown fat works. "This is an exciting step forward," says Dr. Yang. "It illustrates that brown adipose tissue is more than just an energy-burning organ—it plays a pivotal role in enhancing exercise performance and metabolic resilience. This dual function could have significant implications for healthy aging." Related:
Stephen Vatner, MD, who is one of the authors of the study and Director of the Cardiovascular Research Institute at Rutgers University, noted that the study helped researchers show that brown fat could have the potential to increase exercise performance—something not many studies have found before. "There have been a lot of studies showing that exercise can affect brown fat, but fewer studies showing that brown fat can increase exercise performance, the major finding from this research article," he said. Something to note is that the study looked at a potent form of brown fat vs. normal brown fat, and the researchers discussed working to develop a pharmaceutical intervention that may mimic the potent brown fat they discovered.
Dr. Yang cautions that there is still a lot to understand before something like this can be offered, so don't expect a "magic bullet" solution to boost brown fat anytime soon. "And while the study authors offer that the prospect of developing pharmaceutical analogs to activate BAT is exciting, we need a careful evaluation of the long-term safety and potential off-target effects. Enhancing BAT function could, for instance, affect overall energy balance in ways that we don't fully understand yet," she says.
This study sheds more light on what we know about brown fat and how it could be a powerful for enhancing longevity. It's important to keep in mind that the study was performed on mice and may not directly translate to humans until we have more research to confirm the findings. "I would caution that while the results from this study are promising, it's important to note that findings in RGS14 knockout mice may not directly translate to humans. The rapid improvement in exercise capacity is intriguing, yet we must be cautious about overinterpreting these results until similar outcomes are observed in human studies," says Dr. Yang.
Until we know more, you can incorporate some evidence-based methods for activating more brown fat tissue below, while focusing on the foundational tenets that we know are important for longevity and overall health, including: exercise, nutrition and sleep. Related:
According to Dr. Yang, there are several evidence-based ways to help "activate" or convert some of the white fat in your body into the more beneficial brown fat.
"Cold exposure is well-established in activating BAT and promoting the browning of white adipose tissue (WAT)," says Dr. Yang. You can hop in an ice bath, dip into a cold plunge, try cryotherapy or take a cold shower.
"Both resistance and aerobic training have been shown to upregulate markers of browning, such as UCP1, in adipose tissue. Exercise-induced activation of AMP-activated protein kinase (AMPK) in skeletal muscle also plays a role in promoting BAT activity," says Dr Yang. Simply put: you'll want to do cardio and strength training to help activate brown fat.
Dr. Yang says that there's some research that specific foods like chili peppers and green tea contain nutrients that support brown fat. "Capsaicin and capsinoids (found in chili peppers) and catechins (found in green tea) have demonstrated efficacy in clinical trials. Other compounds such as curcumin, quercetin, berberine, lipoic acid, polyunsaturated fatty acids, and royal jelly have shown promising results in animal or in vitro studies, but clinical trials are needed to confirm their effects in humans," she explains.
"Dietary interventions like calorie restriction and intermittent fasting also favor WAT browning and metabolic efficiency," she adds. But always be sure to consult a doctor before trying calorie-restrictive diets or intermittent fasting, since these diets are not safe for everyone.
Up Next:Brown adipose tissue enhances exercise performance and healthful longevity. Healthy Aging.
Ingrid Yang, MD,a board-certified internal medicine physician and longevity science expert
This Is the Type of Fat You *Want* To Have To Stay Healthy as You Age first appeared on Parade on Jul 14, 2025
This story was originally reported by Parade on Jul 14, 2025, where it first appeared.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Many US employers plan to pare health benefits as weight-loss spending soars
Many US employers plan to pare health benefits as weight-loss spending soars

Yahoo

time11 minutes ago

  • Yahoo

Many US employers plan to pare health benefits as weight-loss spending soars

By Amina Niasse NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.

These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs

Yahoo

time11 minutes ago

  • Yahoo

These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs

Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper
Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper

Geek Wire

time13 minutes ago

  • Geek Wire

Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper

A SpaceX Falcon 9 rocket sends Amazon's Project Kuiper satellites into space. (SpaceX / Amazon via LinkedIn) In a case of strange space bedfellows, SpaceX launched 24 satellites for Amazon's Project Kuiper constellation — which is competing with SpaceX's Starlink network to provide internet access from low Earth orbit. A SpaceX Falcon 9 rocket sent the satellites into space from Cape Canaveral Space Force Station in Florida at 2:30 a.m. ET Wednesday (11:30 p.m. PT Tuesday). This was the third launch of operational satellites for Project Kuiper, coming after two batches of 27 satellites each were delivered to orbit in April and June. Those earlier missions made use of United Launch Alliance's Atlas V rockets, but in order to meet its ambitious satellite deployment schedule, Amazon is turning to SpaceX for three Falcon 9 launches. SpaceX enjoys a significant edge over Amazon when it comes to providing satellite broadband access: Starlink has about 8,000 satellites in orbit and more than 6 million subscribers, while Project Kuiper is just getting off the ground. Project Kuiper's satellites are built at an Amazon facility in Kirkland, Wash., not far from the SpaceX complex in Redmond where Starlink satellites are manufactured. Earlier in the evening, a different Falcon 9 rocket lifted off from Vandenberg Space Force Base in California and sent another 26 Starlink satellites into orbit. Both of the Falcon 9 first-stage boosters successfully landed on their respective drone ships in the Pacific and the Atlantic, minutes after launch. About an hour after the Florida liftoff, SpaceX reported that all 24 of the Project Kuiper satellites for the KF-01 mission were successfully deployed — drawing a note of thanks from Panos Panay, Amazon's senior vice president of devices and services. 'Congrats to the amazing Amazon Project Kuiper team on another successful launch, and a big thanks to SpaceX for the ride to space,' Panay said in a LinkedIn post. 'Pumped to have another batch of Kuiper satellites heading into orbit!' Project Kuiper's mission operations center in Redmond took charge of the satellites to check on their health, raise their orbits and prepare for full commissioning. Amazon says it expects to begin delivering service to customers in late 2025. The company's license from the Federal Communications Commission calls for more than 1,600 satellites to be sent into orbit by mid-2026, with the full 3,232-satellite constellation due for deployment by 2029. Unless Amazon and its launch providers pick up the pace dramatically, the company might have to seek an extension.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store